SecBot SecBot
8-K ·Filed Nov 5, 2026

CCCC

C4 Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 19h ago SEC0001628280-26-070560
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The revenue decline is structural (end of Merck/Merck KGaA collaborations) and partially offset by the Roche DAC deal. The key catalysts are the Phase 2 MOMENTUM enrollment completion (Q1 2027) and Phase 1b elranatamab combo data (mid-2027). Monitor for any updates on these timelines or early signals from the elranatamab dose escalation cohorts.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

C4 Therapeutics reported Q3 2026 revenue of $8.5M, down 24.6% YoY from $11.2M, and a net loss of $21.8M ($0.16 per share) vs a net loss of $32.2M ($0.44 per share) in Q3 2025. The revenue decline was due to the conclusion of certain research activities with Merck and Merck KGaA, partially offset by increased revenue from the Roche collaboration. The company's cash position was $274.7M, expected to fund operations to the end of 2028. Clinical milestones remain on track, with Phase 2 MOMENTUM trial enrollment completion expected in Q1 2027 and initial ORR data in H2 2027.

Key Financial Metrics

EPS
−$0.16
est −$0.21 · +23.8%
Revenue
$8.5M
est $8.5M · -0.4% · -24.6% YoY
Rating
beat

Key Facts

  • Q3 2026 revenue was $8.5M, down from $11.2M in Q3 2025
  • Q3 2026 net loss was $21.8M ($0.16 per share), compared to $32.2M ($0.44 per share) in Q3 2025
  • Cash, cash equivalents and marketable securities were $274.7M as of September 30, 2026
  • Company expects cash runway to fund operations to the end of 2028
  • Phase 2 MOMENTUM trial enrollment on track to complete in Q1 2027 with initial ORR data in H2 2027
  • Phase 1b trial of cemsidomide with elranatamab progressing; data from all cohorts expected mid-2027
  • Phase 1b trial of cemsidomide with approved standard of care MM therapies on track to initiate in H1 2027
  • Q3 2026 net loss per share was $0.16 vs consensus estimate of $0.21 loss per share

Financial Impact

Revenue decline of $2.7M (24.6%) YoY; net loss improved by $10.4M YoY; cash burn of $25.7M in Q3 2026

revenuenet losscash position

Risk Factors

  • Revenue decline driven by conclusion of Merck/Merck KGaA collaborations with no new large partnership announced to replace it
  • Clinical-stage biotech with no approved products; all value depends on cemsidomide clinical trial success
  • Cash burn of $25.7M in Q3 2026; at this rate, runway to end of 2028 may be shorter if clinical costs increase

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070560
Exhibit: exhibit991q32026earnings.htm0001628280-26-070560
Document: 0001628280-26-070560-index-headers.html0001628280-26-070560
Document: 0001628280-26-070560-index.html0001628280-26-070560
Document: 0001628280-26-070560.txt0001628280-26-070560
8-K Data (Synthetic)0001628280-26-070560

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026